Year Founded
2021
Ownership
Private
Employees
~100
Stage
Phase 1
Modalities
mRNA therapeuticsmRNA vaccineLipid nanoparticles (LNP)

WestGene General Information

Received dual IND approvals from China NMPA and US FDA for WGc-043, world's first EBV-related mRNA therapeutic cancer vaccine. Completed investigator-initiated trials in nasopharyngeal carcinoma and natural killer T-cell lymphoma showing superior safety and efficacy compared to existing mRNA cancer vaccines.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Chengdu,
China

Drug Pipeline

WGc-043
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to WestGene's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

WestGene Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view WestGene's complete valuation and funding history, request access »